G01N 33/502
For testing non-proliferative effects
Official title: {for testing non-proliferative effects}
G01N33/502 (For testing non-proliferative effects) appears on 3,467 US grants and 6,860 published applications in this corpus.
Search patents in G01N- Granted patents
- 3,467
- Published applications
- 6,860
- Assignees
- 2,444
- Inventors
- 12,329
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 25 | 0 |
| 1998 | 39 | 0 |
| 1999 | 64 | 0 |
| 2000 | 60 | 0 |
| 2001 | 73 | 19 |
| 2002 | 82 | 185 |
| 2003 | 70 | 738 |
| 2004 | 67 | 270 |
| 2005 | 60 | 290 |
| 2006 | 145 | 289 |
| 2007 | 166 | 282 |
| 2008 | 164 | 213 |
| 2009 | 102 | 253 |
| 2010 | 127 | 230 |
| 2011 | 126 | 234 |
| 2012 | 125 | 205 |
| 2013 | 124 | 223 |
| 2014 | 161 | 314 |
| 2015 | 160 | 384 |
| 2016 | 153 | 317 |
| 2017 | 164 | 314 |
| 2018 | 198 | 306 |
| 2019 | 173 | 293 |
| 2020 | 174 | 231 |
| 2021 | 121 | 250 |
| 2022 | 135 | 261 |
| 2023 | 103 | 193 |
| 2024 | 120 | 219 |
| 2025 | 96 | 199 |
| 2026 | 75 | 148 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 33/5023On expression patterns891
- G01N 33/5041Involving analysis of members of signalling pathways709
- G01N 33/5038Involving detection of metabolites per se219
- G01N 33/5026On cell morphology202
- G01N 33/5035On sub-cellular localization196
- G01N 33/5029On cell motility178
- G01N 33/5032On intercellular interactions156
Recent patents
- Complex microfluidic models for ALS including NF biomarkers for ALS research and drug development29 Sep 2026US 12,748,102 B2Cedars-Sinai Medical Center
- Methods for selecting and treating cancer with FGFR3 inhibitors29 Sep 2026US 12,748,103 B2GeneCentric Therapeutics, Inc.
- Methods for detecting phosphorylated alpha-synuclein22 Sep 2026US 12,742,789 B2Prothena Biosciences Limited
- Receptors for cyclic dinucleotides and methods for screening agonists or inhibitors thereof15 Sep 2026US 12,736,524 B2Guangzhou Winkey Technology Co., Ltd.
- Method for detecting and treating Parkinson's disease comprising sebum biomarkers15 Sep 2026US 12,736,525 B2The University of Manchester
- Trem2 agonists for the stimulation of microglia and methods of identification8 Oct 2026US 2026/0306439 A1The Translational Genomics Research Institute
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
- Tertiary amine compounds containing an alkyne or an azide moiety and their use8 Oct 2026US 2026/0308116 A1Assistance Publique-Hopitaux de Paris
Most cited
By later US patents
- High throughput screening assay systems in microscale fluidic devices877US 5,942,443 ACaliper Technologies Corp. · 1999
- Patient classification703US 6,763,307 B2Bioseek, Inc. · 2004
- High throughput screening assay systems in microscale fluidic devices692US 6,046,056 ACaliper Technologies Corp. · 2000
- High throughput screening assay systems in microscale fluidic devices353US 6,267,858 B1Caliper Technologies Corp. · 2001
- Vascularized perfused microtissue/micro-organ arrays324US 6,197,575 B1Massachusetts Institute of Technology · 2001